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Abstract: Campylobacter jejuni is the leading bacterial cause of human gastroenteritis worldwide and
the handling or consumption of contaminated poultry meat is the key source of infection. C. jejuni
proteins FlpA and SodB and glycoconjugates containing the C. jejuni N-glycan have been separately
reported to be partially protective vaccines in chickens. In this study, two novel glycoproteins generated
by protein glycan coupling technology—G-FlpA and G-SodB (with two and three N-glycosylation
sites, respectively)—were evaluated for efficacy against intestinal colonisation of chickens by C.
jejuni strain M1 relative to their unglycosylated variants. Two independent trials of the same design
were performed with either a high challenge dose of 107 colony-forming units (CFU) or a minimum
challenge dose of 102 CFU of C. jejuni M1. While antigen-specific serum IgY was detected in both
trials, no reduction in caecal colonisation by C. jejuni M1 was observed and glycosylation of vaccine
antigens had no effect on the outcome. Our data highlight inconsistencies in the outcome of C. jejuni
vaccination trials that may reflect antigen-, challenge strain-, vaccine administration-, adjuvant- and
chicken line-specific differences from previously published studies. Refinement of glycoconjugate
vaccines by increasing glycosylation levels or using highly immunogenic protein carriers could
improve their efficacy.
Keywords: glycoconjugate vaccines; Campylobacter; chickens
1. Introduction
Campylobacter is the most common bacterial cause of human gastroenteritis globally and is
estimated to have caused 95 million illnesses and 21,000 deaths worldwide in 2010 [1]. Source
attribution studies unequivocally implicate the consumption and handling of contaminated poultry
meat as a key risk factor for human infections [2], and it is estimated that up to 80% of human cases
may be linked to the avian reservoir [3]. In the United Kingdom, 63,946 laboratory-confirmed cases of
human campylobacteriosis were recorded in 2017 [4], with 9.3 cases predicted to be unreported for
every one captured by national surveillance [5] and an estimated annual cost to the economy of GBP
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50 million [6]. Surveys of fresh retail chicken across the United Kingdom during the period 2017–2018
found 56% to be contaminated with Campylobacter [7].
Campylobacteriosis in humans ranges in severity from mild gastroenteritis to acute self-limiting
haemorrhagic diarrhoea involving severe inflammation and may lead to long-term sequelae including
reactive arthritis and inflammatory neuropathies such as Guillain–Barré Syndrome [8–11]. Poultry are
not generally affected by C. jejuni despite carrying large numbers of bacteria in their gastrointestinal
tract [12,13]. However, some studies have reported a decrease in growth performance in chickens
harbouring C. jejuni asymptomatically that may be associated with physiological changes in
the intestines [14]. Moreover, in some broiler breeds C. jejuni has been associated with clinical
signs such as gut damage, inflammatory responses and diarrhoea [15]. Control of Campylobacter in
poultry may, therefore, enhance productivity and welfare in some instances in addition to reducing
a key foodborne zoonosis. It has been predicted that a 100-fold reduction in C. jejuni on chicken
carcasses could reduce human infections by 30-fold [16].
Vaccination is one strategy being developed to control C. jejuni in poultry and several conserved
and immunodominant C. jejuni protein antigens have been explored as candidates either as subunit
vaccines or vectored in live-attenuated Salmonella. These include flagellum-related antigens such
as FlaA, FliD and FspA [17–19], membrane transport proteins such as CjaA and CjaD [20–24],
surface-exposed proteins such as Peb1A, CmeC, CadF and FlpA [18,21], and the superoxide dismutase
SodB [25]. The success of these vaccines, tested using different schedules and C. jejuni strains, has
been variable, with reductions in intestinal C. jejuni loads from 1.5 to 6 log10 being reported. C. jejuni
carbohydrates have also been evaluated as vaccines, including the capsular polysaccharide [26–28]
and N-linked glycans [29–31]. Reductions in C. jejuni colonisation from 4 to 6 log10 have been
reported in chickens vaccinated with an inactive form of Corynebacterium diphtheriae ToxC conjugated
to the heptasaccharide [28]. Further, oral vaccination of chickens with E. coli decorated with the C.
jejuni N-glycan was associated with a reduction in Campylobacter colonisation of up to 10 log10 [29],
and vaccination with outer membrane vesicles of N-glycan decorated E. coli have been reported to
reduce C. jejuni colonisation by almost 4 log10 [30]. Thus, coupling effective C. jejuni protein antigens
with the C. jejuni N-glycan could be a viable strategy to enhance the efficacy of Campylobacter vaccines.
The naturally occurring N-glycosylation system of C. jejuni, encoded by the pgl
locus, is responsible for the production of the assembled heptasaccharide consisting
of GalNAc-GalNAc-(Glc)-GalNAc-GalNAc-GalNAc-diNAcBac (where diNAcBac is
2,4-di-acetamido-2,4,6-trideoxy-D-glucose) on an undecaprenyl-pyrophosphate (Und-PP) carrier.
This glycan is highly conserved in Campylobacter species and is transferred by the enzyme PglB onto
asparagine residues within acceptor proteins containing the D/E-Y-N-X-S/T glycosylation motif [32].
The pgl locus is constitutively expressed and is responsible for the N-glycosylation of numerous
periplasmic and membrane proteins and plays an important role in the colonisation of chickens
and virulence in humans [33–37]. The transfer of heterologous loci for polysaccharide biosynthesis
and C. jejuni pglB into E. coli has enabled the production of recombinant glycoconjugate proteins in
a low-cost and effective process termed protein glycan coupling technology (PGCT) [38,39]. PGCT
enables the production of novel glycoproteins owing to the ability of PglB to transfer any sugar
moiety assembled on an Und-PP carrier onto an acceptor protein containing the D/E-Y-N-X-S/T
glycosylation motif. It has been used to produce novel vaccines against Francisella tularensis [40],
Staphylococcus aureus [41], Shigella flexneri [42] and Streptococci [43] by the addition of O-antigen or
capsular antigens of these pathogens onto carrier proteins. In this study, we used PGCT to couple the C.
jejuni heptasaccharide, which has been reported to be protective against Campylobacter, to the C. jejuni
antigens FlpA and SodB, which have previously been shown to reduce C. jejuni colonisation in chickens
by 3 and 1.5 log10, respectively [18,25]. We evaluated the efficacy of these novel glycoconjugates
relative to unglycosylated variants as subunit vaccines against experimental C. jejuni challenge with
strain M1 at two doses in chickens and discuss the variables that need to be considered in poultry
vaccination studies with C. jejuni.
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2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
Campylobacter jejuni M1 [44] was routinely cultured on charcoal–cephoperazone–deoxycholate
agar (CCDA) at 40 ◦C under microaerophilic conditions (5% O2, 5% CO2 and 90% N2). Liquid cultures
were prepared in Mueller–Hinton (MH) broth that was allowed to equilibrate with the microaerophilic
atmosphere overnight before inoculation and incubation for 16 h with shaking at 400 rpm. For oral
challenge of chickens, liquid cultures were adjusted based on a standard curve of CFU mL−1 relative
to absorbance at 600 nm, with serial dilution where required, to obtain the desired challenge dose.
Inocula used in chicken studies were confirmed by retrospective plating of 10-fold serial dilutions on
CCDA and determination of viable counts after incubation for 48 h.
2.2. Animal Experiments with Layer Chickens
White Leghorn chickens from Campylobacter-free flocks were obtained on the day of hatching
from a Home Office licensed breeding establishment and housed in groups of up to 30 in colony
cages. Groups were of mixed sex and individuals were wing-tagged for identification. Water and
sterile irradiated feed based on vegetable protein (DBM Ltd., Broxburn, UK) were provided ad libitum.
Animal experiments were conducted at the Moredun Research Institute according to the requirements
of the Animals (Scientific Procedures) Act 1986 under project licence PCD70CB48, with the approval of
the local Ethical Review Committee. Chickens were monitored twice daily. Post-mortem examinations
were conducted following culling by cervical dislocation.
2.3. Dose Titration and Colonisation Dynamics of C. jejuni M1
To determine the minimum challenge dose of C. jejuni M1 required for reliable intestinal
colonisation of chickens, an overnight culture containing approximately 109 CFU ml−1 was diluted in
MH broth to prepare four inocula such that a dose of 100 µL would contain approximately 10, 102, 103
and 104 CFU of C. jejuni M1, respectively. At day 15 of life, six chickens per group were challenged
by oral gavage with 100 µL of these cultures. Post-mortem examinations were performed 7 days
post-infection. Contents from both caeca of each bird were mixed together in equal quantities and
10-fold serial dilutions were prepared in phosphate-buffered saline (PBS) and plated on CCDA to
determine viable C. jejuni per gram of caecal contents in individual chickens.
Once the minimum dose of C. jejuni M1 that reliably colonised all chickens in a group was defined,
nine chickens were challenged with the minimum dose at day 15 of life. Post-mortem examinations
of three chickens were conducted on days 1, 3 and 5 post-infection, respectively. Bacteria were
enumerated from both caeca of each bird by plating 10-fold serial dilutions on CCDA as above to
determine the dynamics of C. jejuni M1 colonisation.
2.4. Preparation of FlpA, SodB and Their Glycosylated Variants
Briefly, full length FlpA and SodB from C. jejuni M1 were modified genetically to enable
N-glycosylation by PglB by the addition of one N-terminal and one C- terminal DQNAT glycosylation
site. SodB was further modified to contain a third glycosylation site at position 96–100 by a single amino
acid substitution (Q100T). The proteins contain a signal peptide (PelB) to direct them to the periplasm
for glycosylation and a C-terminal 6-His tag for affinity purification (Figure S1). The constructs
were cloned into an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible plasmid, pEXT20, thus
generating plasmids pFlpA and pSodB (ampR). The plasmids were introduced by electroporation
into E. coli SDB1, a wecA-waaL-strain suitable for PGCT, containing either pACYCpgl (catR), a plasmid
that contains all the necessary genes to produce the C. jejuni N-glycan and a functional PglB to
mediate N-glycosylation [39] or pACYCpgl::pglBKO (catR kanR), where the PglB is non-functional.
This was done to ensure that protein preparation methods were comparable for both the glycosylated
and unglycosylated variants and that any background contaminants would be common to both
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preparations. Transformants selected on LB agar supplemented with 100 µg ml−1 ampicillin and
100 µg mL−1 chloramphenicol produced glycosylated FlpA (G-FlpA) and SodB (G-SodB) whereas
those transformed with pACYCpgl::pglBKO (catR kanR) and selected on LB agar supplemented with
100 µg mL−1 ampicillin and 50 µg mL−1 kanamycin produced unglycosylated FlpA and SodB.
For vaccine production, transformants were grown overnight at 37 ◦C on LB broth with suitable
antibiotics. The following day, the cultures were diluted 1:100 and grown at 37 ◦C under shaking
conditions until an OD600 of 0.5 was reached. A total of 1 mM IPTG was added to the cultures and
they were grown for a further 16 h at 37 ◦C. Cell pellets were collected by centrifugation at 5300× g for
30 min at 4 ◦C, resuspended in ice-cold lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole,
pH 8.0) and subjected to five rounds of mechanical lysis using a pre-chilled Stansted High Pressure Cell
Disruptor (Stansted Fluid Power Ltd., Harlow, UK) under 60,000 psi (410 MPa) in continuous mode.
The lysate was centrifuged at 10,000× g for 60 min at 4 ◦C, and the supernatant was collected for protein
purification using Ni-affinity chromatography. The supernatant was combined with Ni-NTA resin
(Ni-NTA, Qiagen, Germany) for 1 hour at 4 ◦C. The column was then washed with 200 mL of wash
buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0) and the proteins were eluted using
2 mL of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, pH 8.0). Protein fractions
were pooled and concentrated using buffer exchange columns Vivaspin 2 (Vivaproducts, Littleton,
USA) into PBS. The purity of glycoconjugates and antigens was assessed by Coomassie staining of
proteins resolved by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and
western blotting using anti-His (Clone J099B12, BioLegend, San Diego, USA) at 1:1000 followed by
anti-mouse IgG (H+L, Dylight 680, Cell Signaling Technology) at 1:10,000 for protein detection and
soybean agglutinin (Vector Laboratories, Burlingame, USA) at 1:4000, followed by IRDye Streptavidin
(LiCOR) at 1:3000 dilution for glycan detection. Protein concentration was determined by NanoDrop
(ThermoFisher, Waltham, USA), using the extinction coefficient determined for the modified proteins
calculated using ProtParam (Expasy): FlpA extinction coefficient 54,780 M−1 cm−1, Abs (0.1%) = 1.117,
Molecular weight (MW) = 49042.09 Da, and SodB extinction coefficient 47,120 M−1cm−1, Abs (0.1%) =
1.623, Molecular weight (MW) = 28878.43 Da. Quantification of both glycosylated and unglycosylated
antigens for vaccination was based on total amount of protein.
2.5. Trials to Evaluate the Efficacy of FlpA, SodB and Their Glycosylated Variants as C. jejuni Vaccines
Vaccines were prepared by mixing purified glycosylated or unglycosylated proteins with
MontanideTM ISA 70 VG (Seppic, Rungis, France) at a ratio of 30% protein and 70% adjuvant.
Groups of 30 chickens were vaccinated on days 6 and 16 of life intramuscularly with 100 µL protein
divided equally between two pectoral muscles, containing 240 µg of FlpA and G-FlpA or 138 µg
of SodB and G-SodB. Mock-vaccinated chickens were injected with a mixture of 30% PBS and 70%
MontanideTM ISA 70 VG. Two independent trials of this design were performed. At day 20 of life,
4 days after secondary vaccination, birds were challenged by oral gavage with 100 µl of culture
containing either a dose of 107 CFU of C. jejuni M1 (high dose challenge trial) or 102 CFU of C. jejuni M1
(minimum dose challenge trial). In both trials, post-mortem examinations were performed on days 7,
17 and 28 post-infection. The contents from both caeca of each bird were collected as described above
and 10-fold serial dilutions prepared in PBS and plated on CCDA to determine viable counts per gram.
Blood was collected by cardiac puncture at post-mortem examination and serum was stored at −80 ◦C
following the centrifugation of clotted blood at 1000× g for 10 min at 4 ◦C.
2.6. Analysis of Humoral Immune Responses Following Vaccination
Antigen-specific serum IgY levels were quantified by enzyme-linked immunosorbent assays
(ELISA). Briefly, 96-well plates were coated with 0.5 µg mL−1 FlpA, G-FlpA, SodB or G-SodB in
carbonate–bicarbonate buffer and incubated at 4 ◦C overnight. Plates were washed with PBS containing
0.005% (v/v) Tween-20. Serum samples were diluted in PBS and 100 µL of diluted serum was added
per well. Serum dilutions of 1:500 for FlpA and G-FlpA and 1:300 for SodB and G-SodB were selected
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based on the output from chequer-board assays to identify dilutions that would produce absorbance
readings in the linear range. Serum was tested against the glycosylated vaccine antigen to quantify
vaccine-specific responses and against the cognate unglycosylated antigen to determine whether higher
responses were observed against the glycosylated antigens. Control wells were used, to which no
serum was added. To confirm the specificity of the IgY detected, serum from five chickens vaccinated
with FlpA or G-FlpA were tested against SodB and G-SodB and vice versa. Plates were incubated at
37 ◦C for 1 h and then washed as above. Rabbit anti-chicken IgY-horseradish peroxidase (HRP) at 1:3000
(Sigma, UK) was used to detect bound serum IgY. Plates were washed twice. Tetramethylbenzidine
(TMB) substrate (BioLegend, UK) was then added and the plates were incubated for 10 min at room
temperature in the dark. The reaction was stopped using 2 M H2SO4 and absorbance at 450 nm
adjusted against absorbance at 620 nm (A450/620) was measured using a plate reader with background
correction using the values of the control wells (Multiskan Ascent, ThermoFisher, Waltham, USA).
2.7. Statistical Analysis
Statistical tests were performed in GraphPad Prism version 8.00 (GraphPad Software, San Diego,
USA). Differences in colonisation levels and humoral responses between groups of chickens in
the vaccination trials at each time point were analysed using the Kruskal–Wallis test followed by
Dunn’s multiple comparison test. P values of ≤0.05 were considered to be statistically significant. Data
are represented graphically as median values with 95% confidence intervals.
3. Results
3.1. Determining the Minimum Dose of C. jejuni M1 Required for Reliable Intestinal Colonisation
C. jejuni M1 is a human isolate that reliably colonises the gastrointestinal tract of chickens
when administered at a dose of 107 CFU [19,21,25]. At lower doses, colonisation and transmission
dynamics of isogenic signature-tagged variants of M1 can be unstable and unpredictable in chickens
during co-infections [45,46]. Dose titration experiments were performed to determine the minimum
challenge dose of C. jejuni M1 required for reliable colonisation of the caeca, a key site of persistence of
Campylobacter in chickens. At 7 days post-infection, the caeca of five of the six chickens challenged with
10 CFU were colonised by C. jejuni M1 at a median level of 4.9 log10 CFU g−1 (Figure 1A). In contrast,
all six chickens in the groups challenged with 102, 103 and 104 CFU were colonised at a median level
of 9.6, 9.7 and 9.8 log10 CFU g−1, respectively, as previously observed following high dose challenge
with 107 CFU [19,21,25]. A dose of 102 CFU C. jejuni M1 was therefore selected as the minimum dose
required for reliable colonisation based on these results.
To define the colonisation dynamics of C. jejuni M1 following the challenge of chickens with 102
CFU, caecal colonisation levels were determined at days 1, 3 and 5 post-infection (Figure 1B). C. jejuni
M1 could not be detected in the caeca of infected chickens at day 1 and on day 3 colonisation levels in
the chickens ranged from 2.5 to 9.1 log10 CFU g−1. However, by day 5, all chickens were colonised at
a median level of 9.1 log10 CFU g−1.
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Figure 1. Dose titration and colonisation dynamics of C. jejuni M1. (A) White Leghorn chickens were
orally challenged with doses of C. jejuni M1 ranging from 10 to 104 colony-forming units (CFU) and
caecal colonisation was determined at 7 days post-infection. In the group challenged with 10 CFU (•),
five of the six chickens were colonised at a median level of 4.9 log10 CFU g−1. C. jejuni could not be
detected in one chick in this group (#). All chickens challenged with 102 CFU (•), 103 CFU (•) and 104
CFU (•) were colonised at a median level of over 9.6 log10 CFU g−1. A dose of 102 CFU was defined
as the minimum dose for reliable colonisation. (B) The caecal colonisation dynamics of C. jejuni M1
were determined following a challenge with 102 CFU (•). It was observed that bacterial load increased
exponentially over time, reaching a near-maximum median load of 9.1 log10 CFU g−1.
3.2. Effect of Vaccination on C. jejuni Colonisation
His-tagged FlpA and SodB and their glycosylated variants (G-FlpA and G-SodB) were
affinity-purified from E. coli and verified by SDS-PAGE and western blotting to contain proteins
of the correct molecular weight modified with up to two or three C. jejuni N-glycans in the case of
G-FlpA and G-SodB, respectively (Figure 2). However, preparations of G-FlpA and G-SodB were also
found to contain large amounts of unglycosylated proteins. Chickens were vaccinated with purified
proteins or glycoproteins using the schedule previously described to be protective using FlpA as
a vaccine against C. jejuni in chickens [18] (Figure 3A). Caecal colonisation levels in vaccinated and
mock-vaccinated chickens were determined at days 7, 10 and 28 post-infection in two independent
trials of the same design with either 107 CFU C. jejuni M1 (Figure 3B) or 102 CFU (Figure 3C). No
significant reduction in caecal colonisation by C. jejuni M1 was observed in either vaccination trial. In
the minimum dose challenge trial, a slight but non-significant reduction in caecal colonisation was
observed at day 28 post-infection in all groups compared to colonisation levels at previous time points.
Figure 2. Novel glycoconjugate vaccines against C. jejuni. (A) SDS-PAGE was used to confirm the size
of 6-His-purified FlpA (F) and SodB (S) produced in the presence of pACYCpgl::pglBKO (−) and their
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novel glycosylated variants produced in the presence of pACYCpgl (+). (B) Western blotting was used
to confirm the glycosylation status of the vaccines. Anti-His staining in red confirmed the presence of
His-tagged antigens of the correct size while anti-glycan staining in green using anti-soybean agglutinin
confirmed that the antigens were glycosylated in the presence of an active PglB on pACYCpgl. As
expected, the addition of N-glycans at the available glycosylation sites in G-FlpA and G-SodB resulted
in a change in mass of the proteins indicated by the ladder pattern (green arrows with numbers to
signify the number of glycans added) observed above the unglycosylated protein (red arrows).
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Figure 3. Caecal colonisation by C. jejuni M1 post-vaccination and oral challenge. (A) White Leghorn
chickens were vaccinated with FlpA (•), G-FlpA (•), SodB (N), G-SodB (N) or PBS (mock-vaccinated, )
mixed with adjuvant at days 6 and 16 of life followed by oral challenge with C. jejuni M1 at day 20 of
life. Post-mortem examinations were conducted at days 7, 17 and 28 post-infection to study caecal
colonisation levels of C. jejuni M1 and immune responses. (B) Following a high dose challenge of 107
CFU of C. jejuni M1, high caecal loads were observed in all groups that were not significantly different
between vaccinated and mock-vaccinated groups. (C) Similar results were observed in a minimum dose
challenge trial in which chickens were challenged with 102 CFU of C. jejuni M1, further demonstrating
that the challenge dose did not affect the outcome of vaccination.
3.3. Immune Responses to Vaccination
Antigen-specific IgY in sera of chickens was quantified by ELISA using the cognate glycosylated
or unglycosylated forms of the protein as the capture antigen. Significantly elevated antigen-specific
IgY levels were detected in all vaccinated chickens in both trials involving challenge with 107 CFU
(Figure 4A,B) and 102 CFU of C. jejuni M1 (Figure 4C,D) when compared to the mock-vaccinated
chickens. Where birds were vaccinated with G-FlpA or G-SodB, antigen-specific IgY responses were
not significantly different when the glycosylated proteins were used as capture antigen compared
to when the cognate unglycosylated forms were used. Minimal cross-reactivity was observed when
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serum from FlpA and G-FlpA vaccinated chickens was tested against captured SodB and G-SodB and
vice versa (Figure S2), indicating that the IgY responses measured can be attributed to the specific
protein antigens used and not co-purified contaminants from E. coli.
7 17 28 7 17 28 7 17 28 7 17 28 7 17 280
1
2
3
Days post-infection (High dose challenge)
A
45
0/
62
0
FlpA
FlpA
FlpA
G-FlpA
G-FlpA
G-FlpA
G-FlpA
FlpA
Mock
Average
Group:
Coating Antigen:
*
***
*
** *
***
*** *** *****
***
7 17 28 7 17 28 7 17 28 7 17 28 7 17 280
1
2
3
Days post-infection (High dose challenge)
A
45
0/
62
0
SodB
SodB
SodB
G-SodB
G-SodB
G-SodB
G-SodB
SodB
Mock
Average
Group:
Coating Antigen:
***
***
* ***
****
**
**
**
7 17 28 7 17 28 7 17 28 7 17 28 7 17 280
1
2
3
Days post-infection (Minimum dose challenge)
A
45
0/
62
0
FlpA
FlpA
FlpA
G-FlpA
G-FlpA
G-FlpA
G-FlpA
FlpA
Mock
Average
Group:
Coating Antigen:
****** *** ****** ******* **** ****** *** ****
7 17 28 7 17 28 7 17 28 7 17 28 7 17 280
1
2
3
Days post-infection (Minimum dose challenge)
A
45
0/
62
0
SodB
SodB
SodB
G-SodB
G-SodB
G-SodB
G-SodB
SodB
Mock
Average
Group:
Coating Antigen:
** ****
****
****
**
** ***** *
* ****
Figure 4. Induction of humoral immune responses. Levels of serum IgY against the administered
vaccine antigens were determined in chickens vaccinated with FlpA (•), G-FlpA (•), SodB (N), G-SodB
(N) or PBS (mock-vaccinated, ) at all the time points post-infection. High levels of antigen-specific IgY
were found in all vaccinated birds groups compared to mock-vaccinated chickens. This was observed
in both the high dose challenge trial (A,B) as well as the minimum dose challenge (C,D), although
antibody levels were higher in the latter trial. Antibody levels did not have an impact on caecal
colonisation levels. Statistically significant P values of ≤0.05 compared to the mock-vaccinated group
are indicated by asterisks. No differences in serum IgY levels were found between groups vaccinated
with glycosylated and unglycosylated vaccine antigens.
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4. Discussion
Vaccination can be an effective way to control zoonotic bacterial pathogens in poultry, as evidenced
by the reduction in human non-typhoidal salmonellosis and egg and meat contamination following
the implementation of S. enterica serovar Enteritidis and Typhimurium vaccines in laying hens and
broiler breeders in many countries. To be effective for poultry, a C. jejuni vaccine must reduce intestinal
colonisation and provide protection within five to six weeks of life owing to the short lifespan of
fast-growing commercial broilers. Protein antigens like FlpA and SodB have been reported to reduce C.
jejuni colonisation [18,25], as has vaccination with the C. jejuni N-glycan coupled to a protein carrier or
expressed on the surface of E. coli or their outer membrane vesicles [29,30]. In this study, we evaluated
if conjugating the C. jejuni N-glycan to FlpA and SodB could enhance the protective effect of the novel
glycoconjugate vaccines produced.
Traditionally, the production of glycoconjugate vaccines has involved the chemical conjugation
of highly-purified polysaccharides and proteins, which is time- and labour-intensive and often
produces low vaccine yields, making them relatively expensive. Veterinary vaccines must be cheap to
produce and administer on the scale of commercial poultry production. The use of PGCT overcomes
the limitations of conventional glycoprotein production by enabling the production of large amounts
of glycoproteins in E. coli carrying the C. jejuni pgl locus. In this study, we used PGCT to generate
the novel glycoproteins G-FlpA and G-SodB.
Vaccination with these novel glycoconjugates and their cognate unglycosylated forms resulted in
the induction of antigen-specific serum IgY, as expected, and responses were of comparable magnitude
when glycosylated or unglycosylated versions of a protein antigen were delivered. Glycan-specific
serum IgY proved difficult to quantify, owing to the challenge of obtaining highly purified N-glycan for
ELISA. In the absence of this, we used whole C. jejuni cells and N-glycan decorated outer membrane
vesicles from E. coli harbouring the pgl locus [30] as coating antigens for ELISA, but background reactivity
was high and we did not observe differences in serum IgY levels between groups vaccinated with
the glycosylated versus unglycosylated antigens (data not shown). Further, minimal cross-reactivity
was observed when serum from FlpA and G-FlpA vaccinated chickens was tested against captured
SodB and G-SodB and vice versa. Together, these observations suggest a lack of significant anti-glycan
responses with the regimen used. Despite the induction of antigen-specific serum IgY, vaccination did
not significantly reduce the caecal load of C. jejuni as previously observed [47]. While responses to
SodB or G-SodB were broadly similar between the minimum dose and high dose challenge studies,
they were higher for the FlpA and G-FlpA proteins in the minimum dose challenge experiment. This
may reflect the use of separate batches for birds, as we have previously observed between replicated
vaccine trials [25].
Other studies have failed to detect a clear association between antigen-specific IgY and protection
against Campylobacter in chickens; for example Chintoan-Uta et al. reported that the peak in anti-SodB
responses was not coincident with the reduction in caecal colonisation in chickens vaccinated with
a SodB-glutathione-S-transferase (GST) fusion and, moreover, the bulk of SodB was found to be located
in the bacterial periplasm [25]. Chemical bursectomy by the cyclophosphamide treatment of chicks,
which primarily affects the B lymphocyte compartment, has been reported to reduce clearance of C.
jejuni from the jejunum and ileum of birds challenged at 3 weeks of age and sampled up to 7 weeks of
age, although no effect was detected in the caecum [47]. In studies of a longer duration, B cells and
secretory IgA were associated with control of C. jejuni in the caeca by 9 weeks post-infection, although
the authors acknowledged the potential for a cyclophosphamide-sensitive non-B cell compartment to
be involved. The serum IgY levels detected herein may not reflect sIgA responses at relevant sites
of colonisation.
To determine if the challenge dose of C. jejuni affected the outcome of vaccination, two independent
trials were performed, one with a high challenge dose of 107 CFU of M1, as used previously [21,25],
and another with the minimum dose required for reliable colonisation, determined in this study to be
102 CFU of M1. Use of the minimum dose did not reveal protective effects, but it is noteworthy that
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the caecal load of C. jejuni rapidly reached over 9 log10 CFU g−1, even following the delivery of just one
hundred viable bacteria. The levels of natural exposure of broilers to C. jejuni in poultry production
settings are hard to estimate, but vast numbers can be shed when the caeca empty and transmission as
a result of coprophagy is predicted. Studies using contaminated litter or involving indirect challenge
via the introduction of ‘seeder’ birds colonised by C. jejuni would have merit because they simulate
field exposure. Indeed, in a study on the effect of faecal microbiota transplants on C. jejuni colonisation
in chickens, the protective effect was greater in a seeder-bird challenge model than following oral
gavage with C. jejuni [48].
The results of this study are in contrast with previously published observations with FlpA- and
SodB-based subunit vaccines reported to reduce caecal carriage of C. jejuni in chickens [18,25]. This
could be due to differences in the design of the vaccination trials, the challenge strain of C. jejuni, chicken
line, timing of administration, adjuvants or the vaccines themselves. The vaccination schedule selected
for this study was identical to that used by Neal-McKinney et al. to evaluate FlpA as a C. jejuni vaccine.
However, it was previously tested against a different C. jejuni strain (F38011) and in broiler chickens,
and not against C. jejuni M1 in layer chickens, as in this study. Moreover, even though the vaccines
in both studies were delivered intramuscularly and using the same adjuvant, Neal-McKinney et al.
vaccinated chickens first with a GST-tagged 90 mer peptide followed by a His-tagged full-length
FlpA protein. In this study, His-tagged full-length proteins and glycoproteins were used to vaccinate
chickens at both time points. Similarly, although full-length SodB was used here, the antigen used by
Chintoan-Uta et al. was fused to GST [49], and this could potentially have resulted in a distinct tertiary
conformation of SodB compared with the His-tagged variant tested in this study. GST itself has been
shown to be immunogenic [49,50], which could have contributed to the efficacy of SodB in the previous
study. The differences in vaccination schedules between the two studies may also have affected their
outcomes. Chintoan-Uta et al. vaccinated chickens on the day of hatch and on day 14 of life, challenged
them with a high dose of C. jejuni M1 at day 28, and observed a reduction in caecal colonisation by C.
jejuni at 28 days post-challenge. Despite sampling birds at 28 days post-challenge in this study, no
reduction in caecal colonisation was observed. The regimen from the study by Neal-McKinney et al.
was selected in order to determine if protection could be observed within six weeks of life in order to
be useful in a commercial context.
The addition of the C. jejuni N-glycan to our vaccines also did not provide protection against C.
jejuni challenge, as previously reported [29]. This could be explained by the differences in vaccination
schedules and the composition of the vaccines themselves, despite them being tested in layer chickens
in both studies. The N-glycan vaccine described in Nothaft et al. was composed of nine consecutive
acceptor sequons for the addition of C. jejuni N-glycans fused to the C-terminus of a truncated and
inactive variant of the Corynebacterium diphtheriae toxin ToxC, whereas G-FlpA and G-SodB in this study
contain two and three N-glycans sequons, respectively. While the addition of N-glycans at one or all of
the available glycosylation sites in G-FlpA and G-SodB is evident by western blotting, it is possible that
our vaccines contained an insufficient amount of N-glycans to confer protection owing to the presence
of unglycosylated proteins in the preparations. Moreover, ToxC, which is known to be immunogenic
via T cell stimulation and also functions as a natural adjuvant, could enhance the protective effects of
the N-glycan [29]. Thus, it is theoretically possible to increase the efficacy of glycoconjugate vaccines
against C. jejuni by increasing the number of glycosylation sequons and improving glycosylation
efficiency to obtain maximum decoration with N-glycans. Vaccine efficacy may also be enhanced by
adding C. jejuni N-glycans to proteins which are known to be highly immunogenic, such as inactivated
Pseudomonas aeruginosa exotoxin A (ExoA), as reported previously for glycoconjugate vaccines against
Shigella and Francisella [40,51,52].
While we did not observe protection by the novel glycoproteins generated and tested here or their
cognate unglycosylated forms, this could be due to the variability in study design, vaccine design and
delivery or the C. jejuni challenge strain. Moreover, it is important to note that considerable variation
can exist for a candidate Campylobacter vaccine tested across multiple independent replicates. For
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example, while a S. Typhimurium aroA vaccine vectoring CjaA reduced caecal C. jejuni levels by 1.4
log10 CFU g−1 across six independent biological replicates, in some replicates negligible protection was
detected, while in others the reduction in caecal colonisation was closer to 3 log10 CFU g-1 [21]. Further,
these data were themselves inconsistent with the 6 log10 reduction for a near-identical vaccine reported
previously [20]. In turn, this highlights the need for the adoption of consistent protocols that allow
a direct comparison of efficacy across trials and for vaccines to be tested repeatedly and against diverse
bacterial strains. With refinement of glycoconjugate vaccines by altering the levels of glycosylation,
the protein carrier and the regimen, we contend that an efficacious C. jejuni vaccine should be feasible.
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